Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation

Cunrui Li, Mingchao Zhu, Songqi Liu, Jiaming Zhang, Hui Ye, Chen Zhang, Duorui Ji, Haoyang Tang, Yihua Zhang, Jianbing Wu, Zhangjian HuangJournal of Medicinal Chemistry 2024 · DOI

Abstract

Based on the synergistic therapeutic effect of nitric oxide (NO) and Rho-associated protein kinase (ROCK) inhibitors on glaucoma, a series of NO-donating Netarsudil derivatives were designed, synthesized, and their activities in vitro and in vivo were evaluated. Among them, (<i>S</i>)-<b>10e</b> released an appropriate amount of NO in aqueous humor in vitro and displayed potent ROCK inhibition. Topical administration of (<i>S</i>)-<b>10e</b> significantly lowered intraocular pressure in an acute ocular hypertension rabbit model and protected retinal ganglion cells in a magnetic microbead occlusion mouse model. A metabolism investigation revealed that (<i>S</i>)-<b>10e</b> released <b>7a</b>, a metabolite after NO releasing, and <b>13</b>, an active metabolite of (<i>S</i>)-Netarsudil, in rabbit eyes. Notably, introducing an NO donor moiety attenuated ROCK inhibition-induced ocular irritation in an sGC-independent manner, suggesting that the attenuated conjunctival hyperemia effect of (<i>S</i>)-<b>10e</b> is related to the NO-induced protein S-nitrosation of phosphodiesterase 3A (PDE3A). Overall, (<i>S</i>)-<b>10e</b> is a promising candidate for glaucoma treatment.
BibTeX
@article{li2024development,
  author = {Cunrui Li and Mingchao Zhu and Songqi Liu and Jiaming Zhang and Hui Ye and Chen Zhang and Duorui Ji and Haoyang Tang and Yihua Zhang and Jianbing Wu and Zhangjian Huang},
  title = {{Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation}},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01199},
}

Loading related content...

Figure